New hope for aggressive brain cancer? early trial launches for recurrent glioblastoma
NCT ID NCT07538128
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called YSCH-01, alone or with another drug (atezolizumab), in 10 people whose glioblastoma brain tumor has come back. The main goals are to check safety and see how many patients are alive after one year. Participants must be in fairly good health and have a tumor that can be seen on an MRI.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital
RECRUITINGShanghai, Shanghai Municipality, 200040, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a modified herpes virus fight recurrent brain tumors?
- Can a new pill take on brain cancer?
- Can a special MRI reveal hidden brain tumors and guide a stronger radiation strike?
- Radioactive beads take aim at brain tumours
- Two-Drug combo aims to outsmart recurrent brain tumors